Robyn Hunter
Directeur/Bestuurslid bij TENAX THERAPEUTICS, INC.
Vermogen: - $ op 30-04-2024
Actieve functies van Robyn Hunter
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TENAX THERAPEUTICS, INC. | Directeur/Bestuurslid | 28-01-2022 | - |
Independent Dir/Board Member | 28-01-2022 | - | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Financieel Directeur/CFO | 01-08-2022 | - |
Loopbaan van Robyn Hunter
Eerdere bekende functies van Robyn Hunter
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
FORTRESS BIOTECH, INC. | Comptroller/Controller/Auditor | 01-08-2011 | 26-06-2017 |
Financieel Directeur/CFO | 26-06-2017 | 16-08-2022 | |
Bedrijfssecretaris | 01-06-2011 | 16-08-2022 | |
Treasurer | 01-06-2011 | 16-08-2022 | |
Schochet Associates, Inc. | Financieel Directeur/CFO | 01-01-2006 | 01-05-2011 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Comptroller/Controller/Auditor | 01-08-2004 | 01-01-2006 |
Stackpole Corp. | Treasurer | 01-01-1990 | 01-01-2004 |
MUSTANG BIO, INC. | Bedrijfssecretaris | - | - |
Treasurer | - | - | |
AVENUE THERAPEUTICS, INC. | Bedrijfssecretaris | - | - |
CHECKPOINT THERAPEUTICS, INC. | Bedrijfssecretaris | - | - |
Opleiding van Robyn Hunter
Union College (New York) | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 9 |
Canada | 2 |
Tsjechische Republiek | 2 |
Operationeel
Corporate Secretary | 4 |
Director of Finance/CFO | 3 |
Treasurer | 3 |
Sectoraal
Health Technology | 8 |
Consumer Services | 2 |
Producer Manufacturing | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 5 |
---|---|
CHECKPOINT THERAPEUTICS, INC. | Health Technology |
AVENUE THERAPEUTICS, INC. | Health Technology |
FORTRESS BIOTECH, INC. | Health Technology |
MUSTANG BIO, INC. | Health Technology |
TENAX THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Stackpole Corp. | Producer Manufacturing |
Schochet Associates, Inc. | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Health Technology |
- Beurs
- Insiders
- Robyn Hunter
- Ervaring